It Doesn’t Have To End In Tears
Rare diseases aren’t the only field that can benefit from repurposing – companies should also consider breathing new life into old drugs for a much overlooked organ: the eye.
Jeremy Drummond |
Pharma companies are closely scrutinizing existing products to discover if they have activity for new indications, possibly through new routes of delivery. Repurposing comes with challenges as developers must go back to the drawing board to optimize the product for its new purpose, which may require a new formulation or delivery mechanism. However, repurposing also has many advantages:
- existing drugs are likely to have large portion of their non-clinical packages in place
- regulatory authorities offer simpler submissions (e.g., FDA via 505b(II) submission)
- greater understanding of basic biology in other therapeutic areas is uncovering overlaps in certain pathways and targets, especially in immunology and inflammation
- legislation and social media has made orphan indications more attractive.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.